Most Mounjaro side effects are digestive, dose-related, and concentrated in the weeks right after a dose increase. In the placebo-controlled trials the FDA used to build the label, nausea affected 12% of people at 5 mg and 18% at 15 mg, against 4% on placebo. Diarrhea ran 12% to 17%. Vomiting ran 5% to 9%. The serious risks are rarer and sit in a different category entirely, and they are the ones worth memorizing.
Here is what the label actually says, dose by dose, and where the evidence runs out.
Mounjaro's adverse reaction table comes from a pool of two placebo-controlled trials: SURPASS-1, where tirzepatide was used on its own, and SURPASS-5, where it was added to basal insulin. That pool covers 718 people on Mounjaro with a mean exposure of 36.6 weeks. Percentages below are the share of people reporting at least one occurrence.
| Reaction | Placebo (N=235) | 5 mg (N=237) | 10 mg (N=240) | 15 mg (N=241) | |---|---|---|---|---| | Nausea | 4% | 12% | 15% | 18% | | Diarrhea | 9% | 12% | 13% | 17% | | Decreased appetite | 1% | 5% | 10% | 11% | | Vomiting | 2% | 5% | 5% | 9% | | Constipation | 1% | 6% | 6% | 7% | | Dyspepsia (indigestion) | 3% | 8% | 8% | 5% | | Abdominal pain | 4% | 6% | 5% | 5% |
Two things in that table get missed. First, the placebo column is not zero. Nine percent of people on placebo reported diarrhea. Some of what people attribute to the drug would have happened anyway. Second, the dose response is real but not dramatic for every symptom: nausea climbs steadily with dose, while dyspepsia and abdominal pain actually peak at the lower doses.
The label also lists injection site reactions and hypersensitivity reactions among the reported adverse events, and it separately notes eructation, or burping, which is the mechanism behind the sulfur burps people complain about constantly and the label mentions almost in passing.
Wider pooled analyses of SURPASS-1 through -5 (N=6,263) report broader ranges than the two-trial label pool: nausea 12% to 24%, diarrhea 12% to 22%, and vomiting 2% to 13%, with events described as transient and mild to moderate. A published meta-analysis of the tirzepatide program put pooled nausea at 13.3%, 17.9%, and 24.1% for the 5, 10, and 15 mg doses. The label pool is the conservative end of the range; the meta-analyses are the wider one. Both are defensible, which is why you see different figures quoted in different places.
This is the more useful number, and it is smaller than the symptom rates suggest. Gastrointestinal adverse reactions led to discontinuation in 3.0% of people at 5 mg, 5.4% at 10 mg, and 6.6% at 15 mg, compared with 0.4% on placebo.
So at the top dose, roughly one in fifteen people stopped because of digestive side effects. The other fourteen either had none or worked through them. That gap between "reported nausea" and "stopped because of nausea" is the single most misread statistic in this drug class.
Timing matters too. The trial analyses consistently place these events during the dose-escalation period rather than spread evenly across treatment. Symptoms tend to spike after a step up and settle as the body adjusts, which is the entire logic behind the slow titration schedule in the Mounjaro starting guide.
Mounjaro carries the FDA's most serious warning class. The label text: tirzepatide causes thyroid C-cell tumors in rats, and it is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, because the human relevance of the rodent finding has not been determined.
That wording is precise and worth reading twice. The finding is real, it is in rats, and the human relevance is genuinely unresolved. It is not a confirmed human cancer risk, and it is not nothing.
The two contraindications follow from it and from allergy history:
If either applies, Mounjaro is off the table. Our fuller breakdown of exclusion criteria is in who should not take a GLP-1.
Beyond the boxed warning, section 5 of the label lists these warnings and precautions:
Acute pancreatitis. Reported with GLP-1 receptor agonists including Mounjaro. In the trial program it occurred rarely, at rates broadly similar to placebo, but the label warns on it because the consequences are severe. Severe, persistent abdominal pain, sometimes radiating to the back, with or without vomiting, is the signal to seek care rather than wait out.
Acute gallbladder disease. Reported in 0.6% of Mounjaro-treated patients versus 0% of placebo patients in the controlled trials, covering gallstones, biliary colic, and gallbladder removal. Rapid weight loss is an independent gallstone risk factor, which makes attribution messy. More on the symptom picture in tirzepatide and gallbladder issues.
Hypoglycemia with insulin or insulin secretagogues. Mounjaro on its own is not a common cause of low blood sugar. Combined with insulin or a sulfonylurea, it is, and the label anticipates a dose reduction of the other drug.
Acute kidney injury from volume depletion. This is the downstream consequence of the GI side effects, not a separate kidney toxicity. Sustained vomiting or diarrhea leads to dehydration, and dehydration is what harms kidneys.
Severe gastrointestinal adverse reactions, hypersensitivity reactions including anaphylaxis and angioedema, and diabetic retinopathy complications in people with existing retinopathy round out the list.
Pulmonary aspiration under anesthesia. A newer addition. The label describes rare postmarketing reports of aspiration in people on GLP-1 receptor agonists undergoing procedures requiring general anesthesia or deep sedation, who had residual stomach contents despite reported adherence to preoperative fasting. Tell your surgeon and anesthesiologist you are on this drug. Do not assume the standard fasting window covers you.
Finally, the label instructs that a KwikPen must never be shared between patients, even with a new needle, because of bloodborne pathogen risk.
Decreased appetite is a listed side effect at 5% to 11%, and eating less has downstream effects. A DXA substudy of SURMOUNT-1 (n=160, the obesity trial of the same molecule) found that at week 72, tirzepatide participants lost 21.3% of body weight, 33.9% of fat mass, and 10.9% of lean mass, against placebo losses of 5.3%, 8.2%, and 2.6%.
Read the ratio, not the headline. About 75% of the weight lost was fat and about 25% was lean, and that split was roughly the same in the placebo group. Tirzepatide did not produce a worse fat-to-lean ratio than losing weight without it. What it produced was more total loss, so more absolute lean tissue went with it. That is an argument about protein and resistance training, which we cover in tirzepatide and muscle loss.
Note the caveat: this substudy was in the obesity population at obesity dosing, not in the type 2 diabetes population Mounjaro is labeled for.
Same molecule, same manufacturer, different labels. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in type 2 diabetes, and as of August 2026 the FDA expanded it to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk, based on SURPASS-CVOT, a 13,299-participant trial against dulaglutide. Zepbound is the obesity and obstructive sleep apnea brand.
Because the trials enrolled different populations, the adverse event percentages in the two labels are not interchangeable. Hair loss is the clearest example: alopecia appears in the Zepbound adverse reaction table but not in Mounjaro's pooled placebo-controlled table. We could not verify a Mounjaro-specific alopecia rate from a primary source, and it is most often attributed to telogen effluvium from rapid weight loss rather than a direct drug effect. Brand differences are unpacked in Mounjaro vs Zepbound.
How long do Mounjaro side effects last? Trial analyses describe gastrointestinal events as transient and clustered around dose escalation, easing as the body adapts to a given dose. There is no published median duration in days that we could verify, so treat any specific number you see quoted with suspicion.
Do side effects come back at every dose increase? The pattern in the trials is that events concentrate during escalation, which implies each step up can restart them, usually more mildly than the first. Whether to hold at a dose is a prescriber's call, and the label builds in a titration schedule for exactly this reason.
Is nausea a sign the drug is working? No. Nausea rates rise with dose and dose relates to effect, but plenty of people lose weight and improve their A1C without nausea. Practical management is in our guide to tirzepatide nausea.
When should I call a doctor instead of waiting it out? Severe or persistent abdominal pain, especially radiating to the back. Vomiting or diarrhea you cannot keep ahead of with fluids. Signs of an allergic reaction such as swelling or trouble breathing. A neck lump, hoarseness, or trouble swallowing. Vision changes if you have diabetic retinopathy. These are label-level warnings, not internet caution.
Are the percentages the same for compounded tirzepatide? Unknown. Every figure on this page comes from trials of the branded product. No equivalent controlled safety dataset exists for compounded versions.
This page summarizes what the FDA prescribing information and published trials report. It is not medical advice, and dosing decisions belong to your prescriber. The Mounjaro label was last revised April 2026; check the current label for changes.